留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

耐多药结核病的诊断、治疗和防治策略

侍效春 刘晓清

侍效春, 刘晓清. 耐多药结核病的诊断、治疗和防治策略[J]. 协和医学杂志, 2011, 2(4): 305-309. doi: 10.3969/j.issn.1674-9081.2011.04.005
引用本文: 侍效春, 刘晓清. 耐多药结核病的诊断、治疗和防治策略[J]. 协和医学杂志, 2011, 2(4): 305-309. doi: 10.3969/j.issn.1674-9081.2011.04.005

耐多药结核病的诊断、治疗和防治策略

doi: 10.3969/j.issn.1674-9081.2011.04.005
详细信息
    通讯作者:

    刘晓清 电话:010-65295087, E-mail:liuxq_pumch@yahoo.com.cn

  • 中图分类号: R52;R978.3

  • 表  1  抗结核药物分类

    组别 药物分类 药物名称
    1 一线口服药 异烟肼、利福平、乙胺丁醇、吡嗪酰胺、利福喷丁、利福布丁
    2 注射用药 链霉素、卡那霉素、阿米卡星、卷曲霉素
    3 氟喹诺酮类药 氧氟沙星、左氧氟沙星、莫西沙星
    4 二线口服抑菌药 乙硫异烟胺、丙硫异烟胺、环丝氨酸、特立齐酮、对氨基水杨酸钠、对氨基水杨酸异烟肼、氨硫脲
    5 疗效不确切药* 氯法齐明、利奈唑胺、阿莫西林克拉维酸钾、克拉霉素、亚胺培南
    *指耐多药结核病治疗中疗效尚不确切的药物
    下载: 导出CSV
  • [1] World Health Organization. Global tuberculosis control. Epidemiology, strategy, financing[EB/OL]. Genera: WHO, 2009. http://www.who.int/en/.
    [2] World Health Organization. Multidrug and extensively drugresistant TB (M/XDR-TB): 2010 global report on surveillance and response[EB/OL]. Genera: WHO, 2010. http://www.who.int/en/.
    [3] Pandemic (H1N1) 2009-update 110[EB/OL]. Geneva: World Health Organization. http://www.who.int/en/.
    [4] 中华人民共和国卫生部.全国结核病耐药性基线调查报告(2007-2008年)[R].北京: 人民卫生出版社, 2010.
    [5] Cho SN. Current issues on molecular and immunological diagnosis of tuberculosis[J]. Yonsei Med J, 2007, 48:347-359. doi:  10.3349/ymj.2007.48.3.347
    [6] 中国防痨协会.耐药结核病化学治疗指南(2009)[J].中华结核和呼吸杂志, 2010, 33:485-497. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhjhhhx201007003
    [7] Masjedi MR, Tabarsi P, Chitsaz E, et al. Outcome of treatment of MDR-TB patients with standardized regimens, lran, 2002-2006[J]. Int J Tuberc Lung Dis, 2008, 12:750-755. http://www.ingentaconnect.com/contentone/iuatld/ijtld/2008/00000012/00000007/art00011
    [8] Leimane V, Riekstina V, Holtz TH, et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia:a retrospective cohort study[J]. Lancet, 2005, 365:318-326. doi:  10.1016/S0140-6736(05)17786-1
    [9] Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis[J]. Science, 2005, 307:223-227. doi:  10.1126/science.1106753
    [10] Lounis N, Veziris N, Chauffour A, et al. Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration[J]. Antimicrob Agents Chemother, 2006, 50:3543-3547. doi:  10.1128/AAC.00766-06
    [11] Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant Tuberculosis[J]. N Engl J Med, 2009, 360:2397-2405. doi:  10.1056/NEJMoa0808427
    [12] Gandhi NR, Shah NS, Andrews JR, et al. HIV infection in multidrug-and extensively drug-resistant tuberculosis results in high early mortality[J]. Am J Respir Crit Care Med, 2010, 181:80-86. doi:  10.1164/rccm.200907-0989OC
    [13] Keshavjee S, Farmer PE. Picking up the pace-scale-up of MDR tuberculosis treatment programs[J]. N Engl J Med, 2010, 363:1781-1784. doi:  10.1056/NEJMp1010023
    [14] Nathanson E, Nunn P, Uplekar M, et al. MDR tuberculosis-critical steps for prevention and control[J]. N Engl J Med, 2010, 363:1050-1058. doi:  10.1056/NEJMra0908076
    [15] Heller T, Lessells RJ, Wallrauch CG, et al. Communitybased treatment for multidrug-resistant tuberculosis in rural KwaZulu-Natal South Africa[J]. Int J Tuberc Lung Dis, 2010, 14:420-426. http://www.cabdirect.org/abstracts/20103102567.html
  • 加载中
表(1)
计量
  • 文章访问数:  129
  • HTML全文浏览量:  32
  • PDF下载量:  17
  • 被引次数: 0
出版历程
  • 收稿日期:  2011-02-10
  • 刊出日期:  2011-10-30

目录

    /

    返回文章
    返回

    【温馨提醒】近日,《协和医学杂志》编辑部接到作者反映,有多名不法人员冒充期刊编辑发送见刊通知,鼓动作者添加微信,从而骗取版面费的行为。特提醒您,本刊与作者联系的方式均为邮件通知或电话,稿件进度通知邮箱为:mjpumch@126.com,编辑部电话为:010-69154261,请提高警惕,谨防上当受骗!如有任何疑问,请致电编辑部核实。谢谢!